Who Paid My Doc
Agne Paner
Hematology & Oncology Maywood, IL Medical Doctor
NPI 1336303965 CMS profile 196172
2160 S 1St Ave, 2160 Sfirst Ave, Maywood, IL 60153
General payments
$74,632
Research payments
$6,500
Ownership & investment interest
$0
Research they led as principal investigator
$140,356
Through program year 2023, Agne Paner of Maywood, IL is reported in the CMS Open Payments database as having received $74,632 across 54 general payments and $6,500 in research payments paid to them. Separately, studies naming them as principal investigator received $140,356 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $4,060 | 3 | |
| 2022 | General | $15,650 | 15 | |
| 2021 | General | $17,511 | 9 | |
| 2020 | General | $5,369 | 5 | |
| 2020 | Research | $6,500 | 1 | |
| 2019 | General | $32,042 | 22 |
Beside peers
- Agne Paner
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Agne Paner were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Agne Paner | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $32,042 | $529 | $121–$2,516 | $163 |
| 2020 | $5,369 | $339 | $82–$2,213 | $114 |
| 2021 | $17,511 | $263 | $49–$1,965 | $132 |
| 2022 | $15,650 | $416 | $103–$2,395 | $149 |
| 2023 | $4,060 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
55 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Illinois
Mohamad Khair Khasawneh
Hematology & Oncology · Maywood, IL
Michael Bishop
Hematology & Oncology · Chicago, IL
Jamile Shammo
Hematology & Oncology · Chicago, IL
John Berry
Hematology & Oncology · Berwyn, IL
Young Kwang Chae
Hematology & Oncology · Chicago, IL
Irfan Mirza
Hematology & Oncology · Chicago, IL
Related records
Hematology & Oncology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.